Dr. Laxmi Shrikhande She is
Medical Director and Senior
Consultant at Shrikhande Hospital and Research Centre Pvt Ltd,
Nagpur. She is Chairperson Designate ICOG 2020 and Senior
Vice President FOGSI 2012. She
has delivered 11 orations and
450 guest lectures. To her credit,
she has 20 national and 11 international publications.
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation
in the male fetus. In women, AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation. As the size of the residual follicular pool depends on the quantity of
small antral follicles and declines over time, the serum AMH level in women follows a characteristic trajectory: a gradual
decline throughout the reproductive years and a precipitous drop at menopause, becoming undetectable soon after. Thus,
AMH is clinically useful as a screening tool for diminished ovarian reserve (Cui et al. in Fertil Steril 105(02):481–485,
2016). Perturbations in serum AMH are linked with a variety of pathological conditions, for instance, polycystic ovaries
syndrome (PCOS), the pathophysiology likely being the excess follicles in this syndrome which produce increased amounts
of AMH (Dumont et al. in Reprod Biol Endocrinol 13:137, 2015). AMH is also elevated in some ovarian tumors such as
adult granulosa cell tumors, and it can be used as a tumor marker to gauge response to therapy and monitor for recurrence.
Within the domain of assisted reproductive technology, serum AMH assays are widely used to derive prognostic information
such as the chance of successful ovarian stimulation, subsequent embryo quality and even pregnancy rates. Finally, in the
rapidly evolving field of oncofertility, serum AMH holds great promise as a predictor of ovarian reserve after completion
of cancer therapy. Our aim is to put forth an in-depth review of the clinical applications of AMH in contemporary practice.
Keywords : Anti-Müllerian hormone , Assisted reproduction techniques , Oncofertility , PCOS , Targeted therapy
The AMH is a member of the transforming growth factor (TGFβ) superfamily. It is an homodimer disulfde-linked glycoprotein with a molecular weight of 140 kDa. The gene is located on the short arm of chromosome 19 in humans, band 19p 13.3 (Fig. 1).
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male fetus. In women, AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation. As the size of the residual follicular pool depends on the quantity of small antral follicles and declines over time, the serum AMH level in women follows a characteristic trajectory: a gradual decline throughout the reproductive years and a precipitous drop at menopause, becoming undetectable soon after. Thus, AMH is clinically useful as a screening tool for diminished ovarian reserve [1].
Perturbations in serum AMH are linked with a variety of pathological conditions, for instance, polycystic ovaries syndrome (PCOS), the pathophysiologic link being the excess follicles in this syndrome which produce increased amounts of AMH [2]. AMH is also elevated in some ovarian tumors such as adult granulosa cell tumors, and it can be used as a tumor marker to gauge response to therapy and monitor for recurrence. Within the domain of assisted reproductive technology (ART), serum AMH assays are widely used to derive prognostic information such as the chance of successful ovarian stimulation, subsequent embryo quality and even pregnancy rates. Finally, in the rapidly evolving field of oncofertility, serum AMH holds great promise as a predictor of ovarian reserve after completion of cancer therapy.
1. Assisted reproductive technology
2. Fertility preservation
3. Ovarian neoplasms
4. Polycystic ovarian syndrome (PCOS)
5. Pediatric reproductive endocrinology
6. Prediction of early menopause
AMH in the Evaluation of Ovarian Reserve
The total number of oocytes in women is predetermined by genetic factors and invariably declines with time from 1 to 2 million at birth to about 25,000 at age 40 and less than 1000 post-menopause. As the follicular pool depletes, serum inhibin B levels (produced by small antral follicles) decrease, leading to attenuation of the negative feedback on the pituitary. This in turn causes a serial rise in serum follicle stimulating hormone (FSH), consequently leading to earlier follicle recruitment and prompt increase in serum estradiol. Thus, ovarian reserve (OR), a term which denotes the quantity of the residual follicular pool, was classically determined by serum FSH and estradiol (E2) levels in the early follicular phase [3].
As our understanding of reproductive physiology progressed, other alternatives emerged: antral follicular count (AFC) and serum AMH. The antral follicle count (AFC) is measured with the help of ultrasound and correlates well with the amount of primordial follicles remaining, thus providing an indirect measure of ovarian reserve [3]. With ultrasound being operator-dependent, other markers of ovarian reserve have been sought so as to provide an objective assessment.
Serum AMH offers a significant potential advantage in
this regard; being produced by small antral follicles that are
gonadotropin-independent, it demonstrates little intra-cycle
as well as inter-cycle variability in measurements. Indeed,
serum AMH was found to have equivalent performance in
predicting OR as AFC performed by sonography (the gold
standard) in a large systematic review in 2014 [4]. In general, serum AMH level of<1 ng/ml is accepted as a low
ovarian reserve. Thus, serum AMH has established itself
as an integral component in the determination of OR and it
is now the most sensitive marker of ovarian reserve in the
general in vitro fertilization (IVF) population [5].
AMH Measurement for Personalized Ovarian Stimulation
The individualization of controlled ovarian stimulation is an important aim of contemporary infertility practice. AMH evaluation assists in choosing the optimum stimulation protocol, hence reducing the likelihood of ovarian hyperstimulation syndrome (OHSS) or cycle cancelation from nonresponsiveness, leading us closer to the realization of personalized infertility therapy [6]. It also helps in predicting poor responders. Thus, serum AMH assays are being increasingly utilized in clinical practice for this purpose
However, it is also important to recognize the limitations of AMH as its utilization for predicting pregnancy in patients undergoing ART is fraught with diagnostic uncertainties, being neither sensitive nor specific. The possible explanation is that serum AMH is a quantitative marker of small antral follicles and cannot be substituted as a marker of oocyte quality.
Hence, women can be infertile even with high AMH
levels, whereas there are pregnancies described in women
with near-undetectable AMH [7]. Intra-follicular AMH level
may provide more accurate information regarding successful
pregnancy with IVF but needs further research to be validated as a clinical tool [8].
Cancer treatment with chemotherapy and/or radiation is a
known cause of premature ovarian insufficiency (POI) in
reproductive age women and effectively renders them infertile. As rapid strides in cancer therapy allow more survival
than ever before, a discussion regarding fertility preservation
assumes great importance in these women. Several studies report a correlation between serum AMH levels prior to
therapy with the ovarian reserve after completion of treatment [9]. Thus, measurement of AMH can give practical insights into the potential reproductive lifespan after completion of treatment [10].
An important caveat is that although AMH levels assist in determining ovarian reserve post-therapy, an individual susceptibility to gonadotoxicity should also be accounted for. Decanter et al. [12] showed different patterns of ovarian recovery (based on ultrasensitive AMH assays) in 32 patients treated for breast cancer with the same treatment protocol. Patients must also be informed that neither pretreatment nor post-treatment AMH levels predict subsequent successful pregnancy and pregnancies can occur even with a markedly low serum AMH level.
The current gold standard technique for fertility preservation after controlled ovarian stimulation (COS) is oocyte/ embryo vitrification. In healthy patients, recent data have suggested that 8–20 mature oocytes after COS are needed to achieve a reasonable success of live birth, but this number should be individualized according to age [13]. As serum AMH represents a good predictor of response to COS even in cancer patients, it is correlated with the number of oocytes that can be vitrified, and it can also aid in the calculation of recombinant FSH dose in the stimulation protocol [14].
A recent study reported the use of serum AMH to identify
women with a greater likelihood of sufferings from cancer
therapy-related infertility, the rationale being that AMH is a
very sensitive predictor of the number of primordial follicles
in young women with healthy ovaries [15]. Early identification of these women will likewise assist physicians in
making a timely referral to reproductive endocrinologists so
that patients can have an open discussion regarding available
options for preserving their fertility and set realistic expectations regarding future fertility, which in turn will enhance
their quality of life after treatment by orders of magnitude.
Recombinant AMH is emerging as an exciting therapeutic modality in fertility preservation. As discussed, cancer therapy is known to be gonadotoxic through several possible mechanisms, including substantial toxicity on primordial follicles and/or on small antral follicles secreting AMH [16]. According to a newer model of gonadotoxicity termed the ‘burn-out effect,’ cancer therapy, especially cyclophosphamide, induces enormous recruitment of the residual inactive follicles which then undergo atresia [17]. Since AMH is a key regulator of the recruitment of primordial follicles, pre-treatment with recombinant AMH might restrict the gonadotoxicity and follicular depletion that accompany cancer therapy [18].
AMH has been identified as a tumor marker in adult granulosa cell tumors since a long time and levels are elevated in up to 93% cases [19]. More recent reviews have focused on the anti-proliferative effects of AMH on epithelial ovarian neoplasms. Although the precise mechanism is unknown, several hypotheses have been advanced, including inhibition of stem cell factor, activation of apoptotic pathways, as well as arrest of the cell cycle at the G1/S checkpoint in epithelial ovarian cancer cells [20]. Since stem cell factor is also an important mediator of tumor invasion, metastases and development of drug resistance, its suppression by AMH can theoretically reduce the likelihood of these outcomes and augment the relatively dismal 5-year survival rates of this malignancy. Thus, recombinant AMH holds great promise as an investigational targeted therapy in epithelial ovarian cancers.
PCOS is a widely prevalent disorder, affecting more than 100 million women worldwide. Most clinicians diagnose PCOS on the basis of the Rotterdam criteria [21]. However, these features, especially ultrasound appearance of the ovaries, can be menstrual cycle-dependent and/or be affected by oral contraceptive use. Hence, serum AMH which remains stable with cycles and is independent of oral contraceptive use has been explored as a diagnostic marker for PCOS, either alone or in combination with other markers to improve detection.
AMH levels are elevated in PCOS, reflecting the
increased load of small antral follicles [22]. Ovarian surgery like ovarian drilling may reduce these AMH levels,
and overzealous surgeries may lead to premature ovarian
failure or insufficiency. Hyperandrogenism due to either
insulin resistance and hyperinsulinism or LH excess is considered a key driver of intra-ovarian PCOS pathology and
derives from increased synthesis of androgens by the theca
cells of small antral follicles. However, testosterone assays in
reproductive-age females frequently suffer from inaccuracy.
As AMH is produced by granulosa cells of the same small
antral follicles, it may be utilized as an indirect marker of the
degree of intra-ovarian hyperandrogenism in these women.
In light of these discoveries, it is plausible that once diagnostic thresholds have been established, AMH may well be considered indispensable for the diagnosis and assessment
of severity of PCOS.
AMH has numerous applications in clinical pediatrics. As discussed earlier, it is required for the physiologic involution of Mullerian ducts in male fetuses. Since AMH is the product of the Sertoli cells in the testes of males, a positive assay is evidence of testes being present in cryptorchidism and disorders of sex development [23]. In females, AMH can help localize the source of virilization: raised levels are found in testicular tissue-induced virilization, while levels are normal in congenital adrenal hyperplasia [23]. In children treated for ovotestis, AMH can identify the presence of testicular tissue before and after surgical intervention [24]. It is also useful in Klinefelter syndrome as its levels reflect the degree of testicular dysfunction in this condition [25]. Turner syndrome patients are especially likely to undergo accelerated depletion of ovarian follicles, and monitoring of AMH is an excellent indicator of premature ovarian insufficiency in these patients [26]. It is also being investigated as a test for differentiating hypogonadotropic hypogonadism from constitutional pubertal delay. Thus, AMH has established itself as a truly versatile marker in pediatric reproductive endocrinology.
Declining AMH levels indicate gradual decrease in reproductive capacity with age; hence, they may be considered as
a potential marker for menopause.
A recent study showed that every fall of AMH level by
0.10 ng/mL was related to a 14% increased risk of early
menopause (p<0.001) [27]. Another study reported that the
combination of AMH and age was a more reliable predictor of early menopause than age alone [28]. Women above
age of 40 with low AMH levels have shown improvements
in ovarian reserve markers with DHEA supplementation.
DHEA therapy has reported improvement in ovarian function, pregnancy rates and decreased embryo aneuploidy and
miscarriage rate in infertile women predicted to have early
menopause with low AMH [29, 30]
Conflict of interest The authors declare that they have no conflict of
interest.
